NewAmsterdam Pharma at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

NewAmsterdam Pharma takes part in 1 session at CTAD 2026 in Boston. Its program presents the rationale and design of SPINOZA, a phase 2b trial of obicetrapib in preclinical Alzheimer's disease stratified by APOE genotype.

OrganizationCTAD 2026 Attendance
NewAmsterdam Pharma
Naarden, Netherlands
◇Silver Sponsor
newamsterdampharma.com
BiotechSilver Sponsor
Dutch biotech developing obicetrapib, an oral CETP inhibitor that lowers LDL cholesterol, now in a phase 2b trial in preclinical Alzheimer's.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from NewAmsterdam Pharma

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction